These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 12948427)

  • 1. Angiotensin-converting enzyme inhibition or angiotensin receptor blockade in hypertensive diabetics?
    Laverman G; Ruggenenti P; Remuzzi G
    Curr Hypertens Rep; 2003 Oct; 5(5):364-7. PubMed ID: 12948427
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Single versus dual blockade of the renin-angiotensin system (angiotensin-converting enzyme inhibitors and/or angiotensin II receptor blockers) in diabetic nephropathy.
    Jacobsen P; Rossing K; Parving HH
    Curr Opin Nephrol Hypertens; 2004 May; 13(3):319-24. PubMed ID: 15073491
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The effect of angiotensin-converting enzyme inhibitors on the progression of chronic renal failure].
    Bernadet-Monrozies P; Rostaing L; Kamar N; Durand D
    Presse Med; 2002 Nov; 31(36):1714-20. PubMed ID: 12467154
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Blockade of the renin-angiotensin-aldosterone system: a key therapeutic strategy to reduce renal and cardiovascular events in patients with diabetes.
    Burnier M; Zanchi A
    J Hypertens; 2006 Jan; 24(1):11-25. PubMed ID: 16331093
    [TBL] [Abstract][Full Text] [Related]  

  • 5. What is the role of direct renin inhibitors in the treatment of the hypertensive diabetic patient?
    de la Sierra A; Salazar J
    Adv Ther; 2011 Sep; 28(9):716-27. PubMed ID: 21809181
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lessons from trials in hypertensive type 2 diabetic patients.
    Ruilope LM
    Curr Hypertens Rep; 2003 Aug; 5(4):322-8. PubMed ID: 12844467
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of type 2 diabetic nephropathy by blockade of the renin-angiotensin system: a comparison of angiotensin-converting-enzyme inhibitors and angiotensin receptor antagonists.
    Hsueh WA
    Curr Opin Pharmacol; 2002 Apr; 2(2):182-8. PubMed ID: 11950631
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic controversies in hypertension management: angiotensin converting enzyme (ACE) inhibitors or angiotensin receptor blockers for diabetic nephropathy? A case for ACE inhibitors.
    Crook ED; Preddie DC
    Ethn Dis; 2002; 12(4):S3-49-52. PubMed ID: 12477155
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of dual blockade of the renin-angiotensin system on the progression of type 2 diabetic nephropathy: a randomized trial.
    Fernandez Juarez G; Luño J; Barrio V; de Vinuesa SG; Praga M; Goicoechea M; Cachofeiro V; Nieto J; Fernández Vega F; Tato A; Gutierrez E;
    Am J Kidney Dis; 2013 Feb; 61(2):211-8. PubMed ID: 22939518
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comment on: The current practice of using angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in diabetic hypertensive and non-hypertensive patients. Is there a room for vitamin D?
    Alsaeed A
    Saudi Med J; 2021 Jan; 42(1):115. PubMed ID: 33399181
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hypertension in type 2 diabetes--targeting angiotensin.
    Drug Ther Bull; 2005 Jun; 43(6):41-5. PubMed ID: 15966556
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of the renin-angiotensin system, with particular reference to dual blockade treatment.
    Andersen NH; Mogensen CE
    J Renin Angiotensin Aldosterone Syst; 2001 Sep; 2(3):146-52. PubMed ID: 11881115
    [No Abstract]   [Full Text] [Related]  

  • 13. [Diabetic nephropathy and ACE inhibitors].
    Amann B
    Clin Res Cardiol; 2006 Jan; 95 Suppl 1():i83-7. PubMed ID: 16598556
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A clinical trial in type 2 diabetic nephropathy.
    Lewis EJ; Hunsicker LG; Rodby RA;
    Am J Kidney Dis; 2001 Oct; 38(4 Suppl 1):S191-4. PubMed ID: 11576953
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of dual blockade of the renin angiotensin system in hypertensive type 2 diabetic patients with nephropathy.
    Matos JP; de Lourdes Rodrigues M; Ismerim VL; Boasquevisque EM; Genelhu V; Francischetti EA
    Clin Nephrol; 2005 Sep; 64(3):180-9. PubMed ID: 16175942
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The evolution of treatment guidelines for diabetic nephropathy. Strategies integrate JNC VI, more recent protocols.
    Bakris GL
    Postgrad Med; 2003 May; 113(5):35-40, 43-4, 50. PubMed ID: 12764895
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment selection considerations for the hypertensive diabetic patient.
    Christlieb AR
    Arch Intern Med; 1990 Jun; 150(6):1167-74. PubMed ID: 2191633
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Risk and prevention of diabetic nephropathy].
    Ravera M; Re M; Deferrari G
    G Ital Nefrol; 2007; 24 Suppl 38():13-9. PubMed ID: 17922442
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ACE inhibition versus angiotensin receptor blockade: which is better for renal and cardiovascular protection?
    Laverman GD; Remuzzi G; Ruggenenti P
    J Am Soc Nephrol; 2004 Jan; 15 Suppl 1():S64-70. PubMed ID: 14684676
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Competing Effects of Renin Angiotensin System Blockade and Sodium-Glucose Cotransporter-2 Inhibitors on Erythropoietin Secretion in Diabetes.
    Marathias KP; Lambadiari VA; Markakis KP; Vlahakos VD; Bacharaki D; Raptis AE; Dimitriadis GD; Vlahakos DV
    Am J Nephrol; 2020; 51(5):349-356. PubMed ID: 32241009
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.